Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogensAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Caffo et al., Annals of Oncology, doi:10.1016/j.annonc.2020.06.005
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
7th treatment shown to reduce risk in September 2020
 
*, now with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective study of 1,949 metastatic prostate cancer patients on androgen deprivation therapy in Italy. The study found a 1.8% SARS-CoV-2 infection rate and 30.6% mortality among infected patients. Patients were elderly with metastatic castrate-resistant disease, which may explain the high mortality rate. There was no control group, so no conclusions can be made about any potential protective or harmful effect of ADT on COVID-19 infection risk or outcomes.
Caffo et al., 31 Oct 2020, retrospective, Italy, peer-reviewed, 20 authors. Contact: mariaadoracion.romaguera@ssib.es.
This PaperAntiandrogensAll
{ 'indexed': {'date-parts': [[2024, 1, 10]], 'date-time': '2024-01-10T14:20:22Z', 'timestamp': 1704896422770}, 'reference-count': 1, 'publisher': 'Elsevier BV', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 10, 1]], 'date-time': '2020-10-01T00:00:00Z', 'timestamp': 1601510400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'vor', 'delay-in-days': 365, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': { 'domain': ['annalsofoncology.org', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.1016/j.annonc.2020.06.005', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 18]], 'date-time': '2020-06-18T01:42:10Z', 'timestamp': 1592444530000}, 'page': '1415-1416', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 31, 'title': 'On the relationship between androgen-deprivation therapy for prostate cancer and risk of ' 'infection by SARS-CoV-2', 'prefix': '10.1016', 'volume': '31', 'author': [ {'given': 'O.', 'family': 'Caffo', 'sequence': 'first', 'affiliation': []}, {'given': 'V.', 'family': 'Zagonel', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Baldessari', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Berruti', 'sequence': 'additional', 'affiliation': []}, {'given': 'R.', 'family': 'Bortolus', 'sequence': 'additional', 'affiliation': []}, {'given': 'S.', 'family': 'Buti', 'sequence': 'additional', 'affiliation': []}, {'given': 'G.L.', 'family': 'Ceresoli', 'sequence': 'additional', 'affiliation': []}, {'given': 'M.', 'family': 'Donini', 'sequence': 'additional', 'affiliation': []}, {'given': 'P.', 'family': 'Ermacora', 'sequence': 'additional', 'affiliation': []}, {'given': 'G.', 'family': 'Fornarini', 'sequence': 'additional', 'affiliation': []}, {'given': 'L.', 'family': 'Fratino', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Masini', 'sequence': 'additional', 'affiliation': []}, {'given': 'F.', 'family': 'Massari', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Mosca', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Mucciarini', 'sequence': 'additional', 'affiliation': []}, {'given': 'G.', 'family': 'Procopio', 'sequence': 'additional', 'affiliation': []}, {'given': 'M.', 'family': 'Tucci', 'sequence': 'additional', 'affiliation': []}, {'given': 'E.', 'family': 'Verri', 'sequence': 'additional', 'affiliation': []}, {'given': 'P.', 'family': 'Zucali', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Buttigliero', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '8', 'key': '10.1016/j.annonc.2020.06.005_bib1', 'doi-asserted-by': 'crossref', 'first-page': '1040', 'DOI': '10.1016/j.annonc.2020.04.479', 'article-title': 'Androgen-deprivation therapies for prostate cancer and risk of ' 'infection by SARS-CoV-2: a population-based study (N = 4532)', 'volume': '31', 'author': 'Montopoli', 'year': '2020', 'journal-title': 'Ann Oncol'}], 'container-title': 'Annals of Oncology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420398926?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420398926?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 10, 5]], 'date-time': '2021-10-05T07:04:11Z', 'timestamp': 1633417451000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0923753420398926'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10]]}, 'references-count': 1, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2020, 10]]}}, 'alternative-id': ['S0923753420398926'], 'URL': 'http://dx.doi.org/10.1016/j.annonc.2020.06.005', 'relation': {}, 'ISSN': ['0923-7534'], 'subject': ['Oncology', 'Hematology'], 'container-title-short': 'Annals of Oncology', 'published': {'date-parts': [[2020, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'On the relationship between androgen-deprivation therapy for prostate cancer ' 'and risk of infection by SARS-CoV-2', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Annals of Oncology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.annonc.2020.06.005', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 European Society for Medical Oncology. Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit